港股早評:三大指數低開 科技股普跌 新東方在線續漲近6%
格隆匯9月5日丨上週五美股衝高回落連跌三週,港股低開,恆指跌0.79%,國指跌0.99%,恆生科技指數跌1.3%。盤面上,大型科技股普跌,網易、京東跌超2%,阿里巴巴、美團、騰訊皆走低;汽車股再度下跌,再遭巴菲特減持,比亞迪股份低開近6%,家電股、體育用品股、光伏股多數下跌。另一方面,生物科技股走高,康希諾生物漲近9%,吸入用重組新型冠狀病毒疫苗(5型腺病毒載體)作為加強針在中國被納入緊急使用;在線教育股繼續攀升,新東方在線再漲近6%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.